NCT01747083

Food-Effect Bioavailability Study of FDC(Gemigliptin/Metformin HCl Sustained Release) 50/1000mg(25/500mg x 2tablets)

A Randomized, Open Label, Single Dose, Crossover Study to Investigate Food-effect Bioavailability of FDC(Gemigliptin/Metformin HCl Sustained Release) 50/1000mg(25/500mg x 2tablets)Under Fed and Fasting Conditions in Healthy Male Volunteers

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 24 (actual)
• Sponsor: LG Life Sciences · Industry
• Sex: Male
• Age: 20 Years – 45 Years
• Healthy volunteers: Accepted

Summary

This study is designed to investigate the food-effects on FDC(gemigliptin/metformin HCl sustained release) 50/1000mg(25/500mg x 2tablets)

Conditions

• Type 2 Diabetes

Interventions

Type	Name	Description
DRUG	FDC(gemigliptin/metformin HCl sustained release 50/1000mg(25/500mg x 2tablets))

Timeline

• Start date: 2013-01-01
• Primary completion: 2013-03-01
• Completion: 2013-04-01
• First posted: 2012-12-11
• Last updated: 2013-10-24

Locations

1 site across 1 country: South Korea